Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Silgard 9’s Label Updated to Add Long-Term Follow-Up Study Data
October 19, 2022
- Avigan Secured for COVID-19 to Be Stockpiled for Pandemic Flu: Health Minister
October 19, 2022
- Label Expansions for TS-1, Enhertu on PAFSC Agenda on Oct. 31
October 18, 2022
- Japan Panel Recognizes One More Death Possibly Linked to COVID Jab
October 18, 2022
- Health Ministry Research Team to Vet Recall Rules to Address Supply Disruptions
October 17, 2022
- Include COVID Drug R&D Support in New Economic Package: LDP Health Panel
October 17, 2022
- Pfizer’s Precedex Up for PAFSC Review for Pediatric Indication as Japan’s 1st “Specific Use Drug” on Oct. 28
October 17, 2022
- Japan to Prepare Schedule for DX in Medical Fee Revisions by Next Spring
October 14, 2022
- Lawmakers Call for Starting 9-Valent HPV Vaccination Program in April 2023
October 14, 2022
- Contraindication Lifted for Parmodia in Renal Impairment Patients
October 14, 2022
- Japan Looks to Secure 950,000 Courses of Lagevrio by Year-End amid Twindemic Threat
October 14, 2022
- Govt Eyes Designation of Cefazolin, Other Antibiotics as Key Resources
October 14, 2022
- NHI-Market Price Gap at 20-Plus-Outlet Pharmacies 1.8 Times Larger vs. Small Hospitals
October 14, 2022
- Experts Urge MHLW to Present Detailed Data on Generic Manufacturing Costs
October 13, 2022
- Ways to Resolve Drug Lag/Loss, Fuel Development in Japan Up for Debate: MHLW Panel
October 13, 2022
- Panel Members Want More Data on Allocation of NHI-Market Price Margins
October 13, 2022
- MHLW Expert Panel Sorts Out Discussion Points for Full Debate; Focus on Innovation, Stable Supply, and Margins
October 13, 2022
- MHLW Asks Local Govts Not to Discard Near-Expired Pediatric COVID Jabs
October 12, 2022
- Japan to Roll Out BA.4/5 Omicron Boosters on Oct. 13, Inoculations for 6 Months to 4 Years from Oct. 24
October 11, 2022
- MHLW Panel to Discuss Shortening of COVID Booster Interval
October 11, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…